secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZeroStack Corp. (ZSTK)
CIK:        0001790169
Form:       8-K
Filed at:   2026-11-09T21:11:03+00:00
Accession:  0001062993-26-005837
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ZeroStack to sell Phatebo GmbH to New Horizon Pharma for €2.15M; closing needs German FDI clearance
--------------------------------------------------------------------------------

- ZeroStack Corp. (formerly Flora Growth Corp.) agreed to sell 100% of German pharma wholesaler Phatebo GmbH to New Horizon Pharma B.V. for €2,150,000 in a locked-box deal struck at Dec 31, 2025.
- Of the price, €152,709.44 repays a Phatebo loan; the seller-account balance converts to $2,240,161.09 at the ECB's Nov 2, 2026 rate of 1.1216 USD/EUR.
- Phatebo holds a §52a AMG wholesale license, supplies comparators and ancillary drugs for clinical trials, and lists Thermo Fisher Scientific among its key customer contracts.
- Closing requires German foreign-investment (AWV/BMWE) clearance; long-stop date is June 30, 2027, extendable to Dec 31, 2027 if BMWE opens a review proceeding.
- HRV Global Life Sciences Private Limited, indirect sole shareholder of buyer New Horizon Pharma, issued a non-binding term sheet on Sept 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790169/000106299326005837/0001062993-26-005837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790169/000106299326005837/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-26-005837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer